ArcherDX Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- ArcherDX's estimated annual revenue is currently $49.4M per year.
- ArcherDX received $35.0M in venture funding in March 2018.
- ArcherDX's estimated revenue per employee is $155,000
- ArcherDX's total funding is $35M.
- ArcherDX has 319 Employees.
- ArcherDX grew their employee count by 83% last year.
- ArcherDX currently has 16 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Strand Life Sci...||$54.9M||354||N/A||N/A|
What Is ArcherDX?
ArcherDX, Inc., creates catalog and custom next-generation sequencing (NGS) assays that are purpose-built to identify mutations and gene fusions from clinical sample types. By combining novel enrichment chemistry, automated informatics and a user-friendly workflow, Archer products remove the bottlenecks associated with using next-gen sequencing in a translational setting.keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals
Number of Employees
Employee Growth %
|Kyle Lefkoff||Member Board of Directors|
|Matt Franklin||Chief Business Officer||Email Available|
|Pamela Balsley||Tradeshow Manager||Email Available|
|Garry Dallmann||Protein Development And Production Manager||Email Available|
|Randall Evans||Vice President, Diagnostics And Clinical Development||Email Available|
|Ryan Shay||Marketing Manager||Email Available|
|Holly Baden-Tillson||FAS Manager, US|
|Rhonda Schissler||Clincial Data Manager II||Email Available|
|Andrea Flynn||Vice President, Investor Relations & Corporate Communications||Email Available|
|Paul Latimer||Associate Alliance And Revenue Manager||Email Available|
For example, Archer Immunoverse B Cell Receptor (BCR) was launched by ArcherDX, Inc in 2017 to examine human B cell repertoire.
BOULDER, Colo., May 15, 2019 /PRNewswire/ -- ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough ...
BOULDER, Colo., March 5, 2019 /PRNewswire/ -- ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough ...
|2018-03-21||$35.0M||A||Boulder Ventures, Ltd.||Article|
|2019-01-31||Baby Genes, Inc||Article|